521064-34-6
521064-34-6
Chemical Structure
CT 32228
- CAS No.: 521064-34-6
- Formula:C16H13BrClN5
- Molecular Weight:390.66
InChIKey: NUPGPJBRKLLVNK-UHFFFAOYSA-N
SMILES: ClC1=CC(C2=NC(NC3=CC=C(C=C3)Br)=NC(N)=N2)=C(C)C=C1
Biological Activity: CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CT 32228 | 95.27% | CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Douvas MG, et al., Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. Leuk Res. 2006 Aug;30(8):1027-36. [Content Brief]
- [2]. Pagel JM, et al., Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas. Clin Cancer Res. 2005 Jul 1;11(13):4857-66. [Content Brief]
